ArticleFrontiers in medicine2026
Chinese herbal medicine as adjunct therapy improves clinical recovery and reduces multidrug-resistant bacterial load in older adults with pulmonary infection: a retrospective cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Pulmonary infections are common and challenging in older adults due to immune decline, comorbidities, and antimicrobial resistance. This study aimed to evaluate the effects of Chinese herbal medicine as an adjunct therapy to improve immune function and infection outcomes. Methods: This retrospective cohort study was conducted at the Department of Geriatrics, the Second Hospital of Shandong University, China, and included 372 older adults who were admitted between 1 January 2024 and 30 June 2024. Patients were divided into two groups: those who received CHM treatment and those who received conventional treatment. Data were retrieved from the hospital's information system, including patient demographics, clinical status, laboratory results, and treatment outcomes. Outcomes included hospital stay time, febrile duration, symptom recovery, SpO Results: CHM treatment was associated with significantly reduced hospital stay and febrile period, as well as a higher fever resolution rate compared to conventional treatment. Inflammatory markers improved in the CHM group, suggesting a potential immunomodulatory effect. CHM-treated patients also exhibited greater reductions in MDR bacterial counts. These beneficial effects remained consistent in the PSM-matched cohort and were further validated by E-value analysis for robustness against unmeasured confounding. However, no significant differences were found in overall mortality or MDR bacterial reversal. Subgroup analysis showed greater benefits in frail, malnourished, immunocompromised, disabled, and patients with altered consciousness. Conclusion: CHM offers clinical benefits as an adjunct therapy for older adults with pulmonary infections, particularly in improving recovery time and managing MDR bacteria. Further research is required to confirm its efficacy and optimize treatment protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.